Understanding target IOP from the start, considering factors such as percent reduction, absolute reduction, and the impact of every 1-mmHg decrease in IOP, can help support decision making throughout the glaucoma journey.1-3

Target a 20% to 30% IOP reduction

The AAO recommends reducing IOP by 20% to 30% below baseline, with adjustments depending on disease course and severity.1

SEE APOLLO/LUNAR DATA
 

Reduce IOP to <18 mmHg

In the Advanced Glaucoma Intervention Study, maintenance of IOP <18 mmHg was significantly associated with reduced loss of visual field over long-term follow-up.4 A goal of <18 mmHg is also recommended for patients with mild to moderate glaucoma.2

SEE VOYAGER DATA
 

Recognize the 1-mmHg difference

In the Early Manifest Glaucoma Trial, each additional 1 mmHg of IOP reduction in the first 3 months of treatment was associated with an approximate 10% decrease in progression risk.3

SEE VOYAGER DATA

Managing hyperemia and adherence to meet your treatment goals

The Glaucoma Adherence and Persistency Study (GAPS) was designed to identify drivers of patient adherence to topical ocular hypotensive therapy.5 The study found that:

  • right arrow right arrow

    45% of patients on prostaglandin analogs (PGAs) experienced hyperemia, the most commonly reported adverse reaction.6

  • right arrow right arrow

    37% of patients with hyperemia discontinued or switched medication.5

VYZULTA showed a low incidence of hyperemia as well as a <1% discontinuation rate due to any ocular AE in Phase 3 trials.7

INDICATION

VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
  • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
  • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
  • Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
  • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
  • Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
  • Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here to see full Prescribing Information.

References: 1. Primary Open-Angle Glaucoma Preferred Practice Pattern. American Academy of Ophthalmology; 2020. 2. Sihota R, Angmo D, Ramaswamy D, et al. Simplifying "target" intraocular pressure for different stages of primary open-angle glaucoma and primary angle-closure glaucoma. Indian J Ophthalmol. 2018;66(4):495-505. 3. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E; Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121(1):48-56. 4. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130(4):429-440. 5. Friedman DS, Hahn SR, Gelb L, et al. Doctor-patient communication, health-related beliefs, and adherence in glaucoma results from the Glaucoma Adherence and Persistency Study. Ophthalmology. 2008;115(8):1320-1327, 1327.e1-3. 6. Zimmerman TJ, Hahn SR, Gelb L, Tan H, Kim E. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. J Ocul Pharmacol Ther. 2009;25(2):145-52. 7. VYZULTA. Prescribing Information. Bausch & Lomb Inc.

Expand

INDICATION

VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent